Visionary Venture Fund
A venture capital fund that invests in the future of ophthalmology.
Business Model: B2B
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed Visionary Venture Fund Information
Geographic Data
Address: 65 Enterprise
City: Aliso Viejo
State: CA
Zip: 92656
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$118M
Social
Linkedin
Crunchbase
Metrics
5,369,890Website Global Rank
1,718Website Monthly Traffic
Twitter Followers
Description
Visionary is a venture capital firm that invests in the most promising emerging ophthalmology companies in medical devices and pharmaceuticals. With many breakthrough ophthalmic technologies and platforms on the horizon, Visionary Venture Fund was created to help these companies by contributing clinical expertise, commercialization know-how, and growth capital. We work hand-in-hand with today&s;s most promising ophthalmic technologies to create tomorrow&s;s commercial blockbusters. We&s;re looking for visionary entrepreneurs, proven teams, and strong IP to create exciting ideas that address large unmet needs in ophthalmology in order to create market-leading businesses. We are a focused venture capital fund from round A to commercialization. Our target investments range from $500K to $5M in financing rounds ranging from $5M to $15MM. We seek to be lead investors and a partner of choice in our deals as we bring a strong KOL doctor partnership to the table. Visionary’s fund performance net of fees is a 30% IIR, which places it in the top decile of US venture funds.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 3/2016 | Zepto | Series B | 4M |
| 3/2016 | Iantech | Series B | 3.7M |
| 3/2018 | Equinox | Series B | 15M |
| 11/2022 | Re-Vana Therapeutics | Series A | 12.1M |
| 5/2018 | Tear Film Innovations | Series B | 0 |
| 8/2020 | TearClear | Series B | 22M |
| 9/2020 | Orasis Pharmaceuticals | Series C | 0 |
| 11/2017 | Tear Film Innovations | Series A | 0 |
| 3/2017 | RxSight | Series H | 21M |
| 8/2021 | Sydnexis | Series B | 0 |
| 7/2017 | Iantech | Series C | 4.5M |
| 8/2022 | Iantrek | Series B | 23M |
| 10/2016 | CorneaGen | Series A | 10M |
| 6/2018 | Orasis Pharmaceuticals | Series B | 13M |
| 7/2018 | Surface Pharmaceuticals | Series A | 21M |
| 5/2017 | TearClear | Series A | 4.5M |
| 4/2022 | Aurion Biotechnologies | Venture Round | 120M |
| 6/2020 | Re-Vana Therapeutics | Seed Round | 0 |
| 1/2020 | Tarsus Pharmaceuticals | Series B | 60M |
| 4/2022 | Aurion Biotechnologies | Venture Round | 0 |
| 8/2021 | Sydnexis | Series B | 0 |
| 9/2020 | Orasis Pharmaceuticals | Series C | 0 |
| 8/2020 | TearClear | Series B | 0 |
| 6/2020 | Re-Vana Therapeutics | Seed Round | 0 |
| 1/2020 | Tarsus Pharmaceuticals | Series B | 0 |
| 7/2018 | Surface Pharmaceuticals | Series A | 0 |
| 6/2018 | Orasis Pharmaceuticals | Series B | 0 |
| 5/2018 | Tear Film Innovations | Series B | 0 |
| 3/2018 | Equinox | Series B | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
